BCYC Earnings Date: Mar 2, 2027 (Estimated) — Bicycle Therapeutics plc
NASDAQ · Healthcare · Biotechnology
Updated
When is BCYC's next earnings date?
Bicycle Therapeutics plc (BCYC) is expected to report Q4 2026 earnings on Tuesday, March 2, 2027 at 7:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.39 on revenue of $4.0M.
How did BCYC do in its last earnings report?
In its most recent report on Oct 29, 2026 (Q3 2026), Bicycle Therapeutics plc posted EPS of -$0.15 versus the -$0.40 estimate, a beat of 62.4%. Revenue was $34.1M against a $12.2M estimate. The stock's 1-day post-earnings move was -1.5%.
How much does BCYC stock move after earnings?
BCYC beat EPS estimates in 5 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 2.4% (up or down) in the day after earnings.
About Bicycle Therapeutics plc
Bicycle Therapeutics plc, founded in 2009 and based in Cambridge, UK, is a clinical-stage biopharmaceutical company. Its core mission is to create innovative therapeutic classes for diseases currently lacking effective treatments. The company's leading investigational product, BT1718, is a Bicycle Toxin Conjugate (BTC) that is undergoing Phase I/IIa clinical trials. This candidate is engineered to target tumors specifically expressing Membrane Type 1 matrix metalloprotease. Other oncology assets in their pipeline include BT5528, also a BTC in Phase I/II studies, which targets EphA2, and BT8009, currently in Phase I/II clinical development, designed to target Nectin-4. Beyond cancer, Bicycle Therapeutics is advancing THR-149, a plasma kallikrein inhibitor that has completed Phase II clinical trials for the treatment of diabetic macular edema. Their portfolio also includes Bicycle tumor-targeted immune cell agonists (TICAs) such as BT7480, which targets Nectin-4, and BT7455, an EphA2/CD137 TICA presently in preclinical development. The company actively fosters collaborations with various biopharmaceutical entities and organizations, broadening its development efforts into therapeutic areas like anti-infectives, cardiovascular conditions, ophthalmology, and respiratory illnesses. Notable partnerships include a clinical trial and license agreement with Cancer Research Technology Limited and Cancer Research UK. They also maintain research collaborations with AstraZeneca, Sanofi, Oxurion, and the Dementia Discovery Fund. Furthermore, a significant discovery collaboration and license agreement with Genentech is in place for the identification and development of Bicycle peptides for multiple immuno-oncology targets.
🤖 AI Earnings Analysis
Bicycle Therapeutics delivered a strong reported beat, with Q3 revenue of $34M versus $12M expected and loss per share of $0.15 versus $0.40 expected. Still, $66M operating loss and deeply negative margins temper the headline; no catalyst or outlook change was reported.
AI-generated summary — powered by BigEarnings.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-10-29 | Q3 2026 | -0.40 | -0.15 | +62.41% | $34.1M | ✅ Beat | -1.55% | — | — |
| 2026-07-30 | Q2 2026 | -0.53 | -0.72 | -35.85% | $629,000 | ❌ Miss | +3.89% | +2.85% | +12.18% |
| 2026-04-30 | Q1 2026 | -0.62 | -0.87 | -40.32% | $887,000 | ❌ Miss | -0.21% | +8.88% | -0.85% |
| 2026-03-17 | Q4 2025 | -0.97 | -0.29 | +70.10% | $48.0M | ✅ Beat | +0.40% | -14.06% | +4.55% |
| 2025-10-30 | Q3 2025 | -1.08 | -0.85 | +21.30% | $11.7M | ✅ Beat | +7.09% | -24.57% | -8.56% |
| 2025-08-08 | Q2 2025 | -0.94 | -1.14 | -21.28% | $2.9M | ❌ Miss | +2.55% | -1.07% | -6.17% |
| 2025-02-25 | Q4 2024 | -0.88 | -0.75 | +14.77% | $3.7M | ✅ Beat | -1.33% | -6.93% | -21.33% |
| 2024-10-31 | Q3 2024 | -0.78 | -0.74 | +5.13% | $2.7M | ✅ Beat | -2.43% | -1.62% | -15.11% |
Showing last 8 quarters.